Literature DB >> 31917192

KRIT1 loss-mediated upregulation of NOX1 in stromal cells promotes paracrine pro-angiogenic responses.

Federica Finetti1, Irene Schiavo2, Jasmine Ercoli2, Alessia Zotta3, Enrica Boda4, Saverio Francesco Retta3, Lorenza Trabalzini5.   

Abstract

Cerebral cavernous malformation (CCM) is a cerebrovascular disorder of proven genetic origin characterized by abnormally dilated and leaky capillaries occurring mainly in the central nervous system, with a prevalence of 0.3-0.5% in the general population. Genetic studies have identified causative mutations in three genes, CCM1/KRIT1, CCM2 and CCM3, which are involved in the maintenance of vascular homeostasis. However, distinct studies in animal models have clearly shown that CCM gene mutations alone are not sufficient to cause CCM disease, but require additional contributing factors, including stochastic events of increased oxidative stress and inflammation. Consistently, previous studies have shown that up-regulation of NADPH oxidase-mediated production of reactive oxygen species (ROS) in KRIT1 deficient endothelium contributes to the loss of microvessel barrier function. In this study, we demonstrate that KRIT1 loss-of-function in stromal cells, such as fibroblasts, causes the up-regulation of NADPH oxidase isoform 1 (NOX1) and the activation of inflammatory pathways, which in turn promote an enhanced production of proangiogenic factors, including vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE2). Furthermore and importantly, we show that conditioned media from KRIT1 null fibroblasts induce proliferation, migration, matrix metalloproteinase 2 (MMP2) activation and VE-cadherin redistribution in wild type human endothelial cells. Taken together, our results demonstrate that KRIT1 loss-of-function in stromal cells affects the surrounding microenvironment through a NOX1-mediated induction and release of angiogenic factors that are able to promote paracrine proangiogenic responses in human endothelial cells, thus pointing to a novel role for endothelial cell-nonautonomous effects of KRIT1 mutations in CCM pathogenesis, and opening new perspectives for disease prevention and treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCM; COX-2; Cerebrovascular disease; KRIT1; NOX1; PGE2

Mesh:

Substances:

Year:  2020        PMID: 31917192     DOI: 10.1016/j.cellsig.2020.109527

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  4 in total

1.  Phaseolus vulgaris L. var. Venanzio Grown in Tuscany: Chemical Composition and In Vitro Investigation of Potential Effects on Colorectal Cancer.

Authors:  Federica Finetti; Marco Biagi; Jasmine Ercoli; Giulia Macrì; Elisabetta Miraldi; Lorenza Trabalzini
Journal:  Antioxidants (Basel)       Date:  2020-11-26

2.  Protein kinase Cα regulates the nucleocytoplasmic shuttling of KRIT1.

Authors:  Elisa De Luca; Andrea Perrelli; Harsha Swamy; Mariapaola Nitti; Mario Passalacqua; Anna Lisa Furfaro; Anna Maria Salzano; Andrea Scaloni; Angela J Glading; Saverio Francesco Retta
Journal:  J Cell Sci       Date:  2021-02-04       Impact factor: 5.285

3.  Heterozygous Loss of KRIT1 in Mice Affects Metabolic Functions of the Liver, Promoting Hepatic Oxidative and Glycative Stress.

Authors:  Raffaella Mastrocola; Eleonora Aimaretti; Gustavo Ferreira Alves; Alessia Sofia Cento; Claudia Fornelli; Federica Dal Bello; Chiara Ferraris; Luca Goitre; Andrea Perrelli; Saverio Francesco Retta
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

4.  Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.

Authors:  Miguel Alejandro Lopez-Ramirez; Catherine Chinhchu Lai; Shady Ibrahim Soliman; Preston Hale; Angela Pham; Esau J Estrada; Sara McCurdy; Romuald Girard; Riya Verma; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Robert Shenkar; Orit Poulsen; Gabriel G Haddad; Richard Daneman; Brendan Gongol; Hao Sun; Frederic Lagarrigue; Issam A Awad; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.